Phase II study evaluates innovative combination of AgenT-797 (iNKT cell therapy), botensilimab (CTLA-4 inhibitor), and balstilimab (PD-1 inhibitor) in PD-1 refractory gastroesophageal cancer patients.
Agenus will showcase interim data from a Phase 2 study combining BOT/BAL with iNKT cell therapy AgenT-797 in refractory gastric cancer patients at the AACR IO Annual Meeting.
CARsgen completed enrollment in a pivotal Phase 2 trial of satricabtagene autoleucel (satri-cel), a CLDN18.2-targeted CAR-T therapy, for advanced gastric/gastroesophageal cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.